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As patients advance through the model, their BMD progresses and they are at risk
of fracture (hip, vertebral, other) and of death. BMD changes, fracture risks and
mortality were all based on the Dubbo Osteoporosis Epidemiology Study (DOES).
Utility values were based on the patients fracture status. Evidence for the efficacy
of alendronate in the prevention of fracture was the clinical fracture arm of the
Fracture Intervention Trial (FIT). RESULTS: The incremental cost per QALY of
broadening access to alendronate compared with current practice was $34,808
(incremental costs of $783 per patient with 0.0225 QALYs gained). Broadening ac-
cess to alendronate resulted in fewer fracture-related deaths (301 per 100,000 pop-
ulation), hip fractures (904), vertebral fractures (259) and other fractures (1098).
CONCLUSIONS: Broadening primary prevention treatment of osteoporotic fracture
with alendronate to individuals aged 70 years with BMD T–scores  – 2.5 will
prevent fractures and save lives at good value-for-money.
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OBJECTIVES: Increasing real-life adherence to bisphosphonates therapy is impor-
tant to achieve the clinical benefits of reducing fractures reported in randomized
clinical trials (RCTs). The aim of this pharmacoeconomic analysis was to determine
the cost-effectiveness of a pharmaceutical care intervention program in commu-
nity pharmacies, aimed to increase bisphosphonates adherence for the prevention
of osteoporotic fractures. METHODS: A decision analytical model was constructed
with a time horizon of three years, discounting at 4.0% and 1.5% annually for costs
and effects, respectively. A Dutch healthcare provider’s perspective was adopted.
Adherence and efficacy data were gathered from a Dutch pharmaceutical care
program in community pharmacies (the MeMO intervention). The association be-
tween bisphosphonate adherence and osteoporotic fractures was modelled using
Dutch clinical studies. Recent and upcoming reimbursement policy changes in The
Netherlands were modelled with a scenario of therapeutic substitution, character-
ized by drastically lower drug prices. RESULTS: Adherence to bisphosphonates
therapy in The Netherlands was 68.3%. The pharmaceutical care intervention pro-
gram increased bisphosphonates adherence to 83.9% (P0.001). If the intervention
program would be introduced nationwide in community pharmacies, 337 osteopo-
rotic fractures would be prevented and 47 quality-adjusted life years (QALYs)
would be gained. Additional medication and intervention costs were €1,738,000;
the cost-savings due to reduced fractures were €998,000. The cost-effectiveness of
the pharmaceutical care intervention was €16,000 per QALY. When drug prices
decline following therapeutic substitution policies, the intervention will be
cost-saving. CONCLUSIONS: Pharmaceutical care programs in community phar-
macies, such as the MeMO intervention, can improve bisphosphonate adherence,
resulting in a considerable number of osteoporotic fractures being prevented.
Therapeutic substitution policies that lower drug prices will increase the cost-
effectiveness of interventions that increase adherence. This study demonstrates
the value of pharmaceutical care programs in community pharmacies to increase
therapy adherence.
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OBJECTIVES: Dupuytren’s contracture (DC) is a progressive disorder that limits
hand function and impacts on patient’s ability to work or to perform their daily
activities. Current standard of care is limited fasciectomy, a surgical procedure that
removes part of the affected cord. Collagenase clostridium histolyticum (CCH) is the
first licensed pharmacological treatment for DC patients with a palpable cord. This
study aims to estimate costs of CCH versus fasciectomy in Portuguese DC patients.
METHODS: A cost minimization approach was adopted, with effectiveness as-
sumed to be equivalent for CCH and fasciectomy. Resource use was elicited
through a panel of five Portuguese experts with extensive clinical experience. Fa-
sciectomy’ direct costs of included surgery in-patient cost and post-surgery costs:
follow up outpatient visits and physiotherapy. CCH’ direct costs included vials
costs, administration of injection in an outpatient setting and a follow up outpa-
tient visit. Fasciectomy induced indirect costs were estimated by the human cap-
ital method. Unit costs were extracted from Portuguese literature and official
sources. Societal perspective was adopted. RESULTS: Average direct cost per pa-
tient for CCH and fasciectomy were respectively 2,099€ and 2,366€. Average saving
per patient is 267€, a reduction of 11% direct fasciectomy costs. Although inclusion
of indirect costs can introduce some uncertainty due to measurement error, they
should be analysed given their relevance to the society: average saving per patient
estimate is 1,407€ when we include productivity costs. CONCLUSIONS: CCH is a
convenient, minimally invasive, effective and generally well tolerated alternative
to surgery for DC’ patients. Adoption of CCH as an alternative to fasciectomy offers
a choice for DC’ patients, and provides an efficient approach to the treatment of DC
by reducing the demand for physiotherapy and in-patient services. On average,
CCH is cost saving in Portugal compared with fasciectomy and induces superior
savings when indirect costs are included.
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OBJECTIVES: Denosumab has been shown to be a cost-effective use of NHS re-
sources for the treatment of postmenopausal osteoporosis in England and Wales.
This study assessed the cost-effectiveness of denosumab given Scottish treatment
and resource use patterns. METHODS: A probabilistic model employed in a recent
submission to NICE was used with resource use amended to reflect local expert
advice. This indicated zoledronate requires an annual pre-infusion assessment
appointment and that patients failing on, or unable to take oral bisphosphonates
are referred to secondary care for advice on further treatment. Denosumab is mod-
elled as initiated in secondary care, with subsequent injections in primary care.
Fracture risk for 70 year old women with bone mineral density T-score 2.5 was
based on a published algorithm and accounted for prior fracture. Relative efficacy
of osteoporosis therapies was based on meta-analysis and adjusted indirect com-
parison. Utilities reflected patients’ age and modelled health states. All therapies’
administration was costed using NHS Reference and PSSRU costs. Drug costs were
from the British National Formulary. Costs and utilities were discounted at 3.5%.
RESULTS: Denosumab dominated strontium ranelate and IV ibandronate in both
cohorts, and was cost-effective versus raloxifene (£4,339/QALY without prior frac-
ture and dominant in patients with prior fracture). Denosumab was also cost-
effective against no treatment: cost/QALY £22,380 and £9,618 in patients without
and with prior fracture respectively. IV zoledronate and denosumab each produced
very similar QALYs in the two cohorts, however, denosumab’s costs were approx-
imately £1,000 lower in each. Zoledronate’s cost/QALY ratios against denosumab
were £120,000 and £50,000, i.e. zoledronate was not cost-effective against deno-
sumab. Denosumab had the greater probabilities of being cost-effective at thresh-
old values of £30,000/QALY in both cohorts. CONCLUSIONS: Denosumab was
shown to be cost-effective against all comparators in both primary and secondary
care settings. Compared with zoledronate, denosumab may be a better use of NHS
resources.
PMS45
COST-UTILITY AND BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL
PLUS METHOTREXATE FOR THE TREATMENT OF MODERATE-TO-SEVERE
ACTIVE RHEUMATOID ARTHRITIS IN GREECE
Maniadakis N1, Boumpas D2, Kourlaba G1, Christou P3, Anargiros I3, Smets E4, Purcaru O4
1National School of Public Health, Athens, Greece, 2University of Crete, Heraklion, Greece, 3UCB
A.E, Alimos, Greece, 4UCB S.A, Brussels, Belgium
OBJECTIVES: To evaluate the cost-utility and budget impact (BI) of certolizumab
pegol (CZP) as an add-on therapy to methotrexate (MTX) versus other first line
biological DMARDs, in the treatment of adult patients with active RA who did not
respond adequately to DMARDs, including MTX, in Greece. METHODS: A Markov
(cohort health state transition) model was developed to evaluate the cost-utility of
CZP versus other TNF- inhibitors recommended in Greece (etanercept [ETA], ada-
limumab [ADA] and infliximab [IFX]). Treatment efficacy was measured using the
ACR-responses (ACR20/50/70) at 6 months. ACR estimated rates were based on
adjusted indirect comparison (MTX as common comparator) of published clinical
trials. Utilities were derived from EQ-5D data from CZP RA clinical trials. Clinical
history/resource use data came from published literature. Sensitivity analyses
were conducted. The BI of CZP as an add-on therapy to MTX was estimated from
payer perspective over 2011–2015. The alternatives to CZP include all TNF- inhib-
itors recommended in Greece (etanercept, adalimumab, infliximab, golimumab).
Epidemiological data were used to estimate the RA population eligible for CZP
therapy. Published 2011 hospital unit costs (drug acquisition, administration, mon-
itoring, resources) in both analyses were taken from Greek routine sources/expert
opinion. Base case analysis assumed a payer perspective, costs discounted at 3.5%
(CU/BI), a lifetime horizon, with outcomes discounted at 3.5% (CU), 75kg patient-
fixed average weight (BI). RESULTS: Base case analysis indicated that CZP is cost-
effective compared with all combination therapies considered (at €60,000(3xGDP/
capita) willingness-to-pay threshold), with an incremental cost-effectiveness ratio
of €19,181/QALYs, €32,208/QALYs, €22,349/QALYs versus ADAMTX, ETAMTX
and IFXMTX, respectively. In terms of BI, the introduction of CZP on the Greek
market produced cumulative net savings of €7.68M during 2011–2015.
CONCLUSIONS: This analysis shows that CZPMTX is cost-effective versus. the
other TNF- inhibitors recommended in Greece for the treatment of RA and its use
is anticipated to result in budgetary net savings.
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OBJECTIVES: To evaluate the cost-utility of CZP compared with standard-of-care
first-line administered TNF-inhibitors  MTX in the treatment of moderate-to-
severe RA in Spain.METHODS:A Markov (cohort health state transition) model was
developed to evaluate the cost-utility of CZP versus the other TNF-inhibitors li-
censed and recommended in Spain (etanercept [ETA], adalimumab [ADA], and
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